Charity Breast Cancer Now has described the failure to negotiate a fair price of Enhertu as “utterly heartbreaking”.

Barbara O’Brien, MD, discusses the background behind the phase 2 TBCRC049 study investigating the combination of tucatinib, trastuzumab, and capecitabine for the treatment of patients with ...

The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers ...

Financial incentives provided to hospitals in Japan led to a significant increase in biosimilar oncology drug prescriptions.

The National Institute for Health and Care Excellence (Nice) said it is "extremely disappointed" it will be unable to ...

Nice said it was ‘extremely disappointed’ it will be unable to recommend trastuzumab deruxtecan, sold under the brand name ...

AZ and Daiichi Sankyo have said that NICE's decision on Enhertu exposes how new methods and processes the agency uses to ...

Adding an anthracycline to adjuvant chemotherapy for TOP2A-normal early breast cancer significantly improved disease-free survival (DFS) but not overall survival (OS) at 10 years, and doubled the risk ...

Breast cancer patients in England and Wales will not have access to the drug after pricing negotiations failed between NICE and drugmakers.

KEYTRUDA, in combination with trastuzumab, fluoropyrimidine- and platinum containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic ...